Journals Retract 13 Papers from Heart Stem Cell Lab

It’s the latest fallout from an investigation by Harvard and Brigham and Women’s into work overseen by Piero Anversa.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ABOVE: © ISTOCK.COM, BAHADIRTANRIOVER

The cardiac stem cell field has had a rough run in recent months. Not only have scientists piled up evidence that cardiac stem cells don’t exist, but one of the leading proponents of the cells has just had a dozen papers retracted.

On Wednesday, Circulation pulled three papers from the lab of Piero Anversa, formerly at Harvard Medical School and Brigham and Women’s Hospital, while Circulation Research retracted 10. Retraction Watch notes that Anversa was not a coauthor on one of the papers, but it came from his lab.

The retractions come after Harvard and Brigham and Women’s concluded an internal investigation and recommended in October that 31 of Anversa’s publications be rescinded because of fraudulent data. A clinical trial based on discoveries that came from Anversa’s lab was also put on hold.

Among the retracted studies are two 2010 Circulation Research papers (each cited more ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies